Digital Therapeutics Summit Moderator & Speakers

Dan Leonard

Dan Leonard — Moderator 
Principal
Granite Capitol Consulting LLC 

With over 20 years of association management at the highest levels, Dan Leonard has a unique 360-degree view of the health care ecosystem in America from the payer, innovative and generic pharma, and patient perspectives. Leonard is the founder of Granite Capitol Consulting where he works with corporations, nonprofit associations, and professional societies in the health care space on strategic planning, advocacy, policy, and public affairs.   

From 2020 to 2022, Leonard served as the president and chief executive officer of the Association for Accessible Medicines (AAM), the nation’s trade association for the makers of generic and biosimilar medicines which fill 9 out of 10 prescriptions in the United States. Prior to joining AAM, Leonard served as president and chief executive officer of the National Pharmaceutical Council (NPC) which sponsors and conducts research on a number of critical health policy issues. During his 12 years as CEO, NPC played a leadership role in the evolving areas of pharmaceutical value assessment, value-based contracting, and the importance of maintaining a robust innovation ecosystem. 

Prior to his time in the pharmaceutical space, Leonard was an executive responsible for public affairs and advocacy at one of the nation’s leading payer organizations, America’s Health Insurance Plans (AHIP), the trade association representing companies providing health insurance coverage in the United States. He also served for six years on the Board of Directors of the National Health Council, whose core membership includes the nation’s leading patient organizations.   

Before entering the Washington association community, Leonard developed significant experience in politics and government, including time spent in presidential campaigns, leading communications at the National Republican Congressional Committee (NRCC) and serving as chief of staff for a member of the Congressional leadership. Early in his career, Leonard worked as a television news reporter covering presidential primary politics in his home state of New Hampshire. He also worked in newsrooms in Boston, Pittsburgh, and Vermont.  

Leonard has a bachelor’s degree in journalism from Marietta College in Marietta, Ohio where he currently serves on the Board of Trustees, and he received a master’s degree in government from the Johns Hopkins University.

Tit Ala'illma

Titiimaea Ala'ilima, MSE 
VP Applied Data 
Akili Interactive Labs, Inc.

Titi Ala'ilima studied Electrical Engineering at the University of Pennsylvania, graduating with an MSE. He joined MIT Lincoln Laboratory doing mixed-signal circuit design and semiconductor layout. But the sensitive and esoteric nature of the work led him to seek a career building things with broader access and impact. Since the dot-com era, he has been building data-rich software products, first as a Web developer, progressing through back-end systems, and ultimately as a data engineer and data scientist. 
 
As a parent of an autistic child, and as a student of human learning and development in general, he pursued an interest in neuroscience. Coupled with his machine learning experience and observations of his child's interactions with games, he started developing a vision of games that adapt to the player to tap into their unique motivation and to address their unique needs. He found Akili in 2015, already underway in clinically validating such a product with an eye towards releasing it as a Prescription Digital Therapeutic. Since then, as VP of Applied Data, he has driven the development of various data practices within Akili, including data engineering, data science, and biostatistics.

Jeffrey Abraham

Jeffrey Abraham, MSPT, MBA 
Vice President, Digital Health Practice Co-Lead 
Health Advances 

Jeff co-leads the Digital Health and Health IT Practice at Health Advances, where he focuses his time on providing digital health commercialization strategy services for digital therapeutics, digital health, biopharma, and medtech clients. He holds extensive expertise related to commercialization, global market access, product development, and evidence generation. 
 
Jeff serves as a task group lead for the Digital Therapeutics Alliance, the National Council of Prescription Drug Program, as well as serving on the AMCP DTx Advisory Group and the Founding members council of the Digital Medicine Society. 
 
Prior to joining Health Advances, Jeff served in executive and leadership roles in access, trade, and commercial functions at Akili Interactive. During his time at Akili Interactive, Jeff focused on payer strategy, reimbursement, pricing, strategic partnerships, evidence generation, distribution, launch planning and execution. 
 
Prior to his time at Akili Interactive, Jeff served as Senior Director for the Medicines Company in their Value Development department. He supported commercialization and global launch of novel drug device combo and the development of additional perioperative and cardiovascular products. Prior to The Medicines Company, Jeff served as a consultant for GfK working in global market access and commercialization. His work spanned numerous therapeutic areas across drug, devices, and diagnostics.

Lucas Beal

C. Lucas Beal, Juris Doctor 
Partner 
Hutchison, PLLC

Lucas has a passion for helping businesses in the life sciences sector  successfully manage a wide variety of legal issues. His practice focuses on data privacy and security, employment law, contract negotiation, and corporate law.
 
Prior to joining Hutchison, Lucas worked in the life sciences and clinical trial industry as in-house legal counsel for PRA Health Sciences. In this role, he drafted and negotiated commercial contracts and assisted PRA on regulatory compliance issues and privacy issues. Before his work at PRA, Lucas presided over unemployment benefits hearings while working with the North Carolina Division of Employment Security. He has practiced at other North Carolina firms advising clients on employment law and a variety of corporate transactions. Before attending law school, Lucas worked in the financial industry.

Edward Cox

Edward Cox
General Manager & Head,​ Pfizer Digital Health & Medicines​
Pfizer, Inc.

Edward Cox is an innovative, inspiring, and relentless life science and digital health executive with a background in pharma, tech, investment banking, and public markets.  He is committed to advancing the digital health sector as it strives for patient outcomes, clinical results and commercial viability.  He currently serves as the leader of Pfizer’s industry-first digital health and medicines business unit.

Ed previously served as Executive Vice President, Strategic Alliances & Global Head of -EVERSANA’s Digital Medicine Practice. In this role, he guided Digital Medicine and Digital Therapeutics companies to directly commercialize products and identified new avenues for pharmaceutical companies to effectively deploy digital therapies into their product portfolios to maximize the value and impact.

Before that, Ed led Dthera Sciences as CEO from inception into a pioneering digital therapeutics company that was granted FDA Breakthrough Device designation for the treatment of Alzheimer’s disease and recognized as a top 10 company in the Digital Therapeutics sector.

Additionally, he served as chairman of the first digital therapeutics conferences, including DTxDM, DTx East, and the inaugural DTx Europe (London, UK). He also served as chair, moderator, or speaker at many other digital therapeutic and digital medicine events throughout the world. His background also includes executive leadership across numerous industries including pharma, technology, investment banking, and public markets.

Ed holds MS in Management from the Warrington College of Business at the University of Florida as well as a BS in Telecommunications from the University Florida.

Jessilyn Dunn

Jessilyn Dunn, PhD 
Assistant Professor 
Duke University

Dr. Jessilyn Dunn is an Assistant Professor of Biomedical Engineering and Biostatistics & Bioinformatics at Duke University. A leading expert in mobile health, she has pioneered research on wearables and their applications in health care. She is the founder of the Digital Biomarker Discovery Pipeline (DBDP). Dr. Dunn’s research focus is on tracking chronic and infectious diseases with wearable sensors. 


 

Adam Hoye-Simek

Adam Hoye-Simek, PharmD, RPH 
Senior Pharmacy Manager of Utilization Management 
Devoted Health Plan

Adam Hoye-Simek is the Senior Pharmacy Manager of Utilization Management for Devoted Health Plan. Devoted Health provides innovative Medicare Advantage in 13 states across the country and has been the fastest-growing Medicare Advantage plan in the country for multiple years. Adam oversees the organization’s pharmacy-related benefits that fall under Part B. He leads clinical strategy, CMS auditing, appeals, and manages the day-to-day operations for the department. He has exclusively written and maintained the department's library of over 30 coverage policies. He led the company’s implementation of biosimilar-focused step therapy and continues to lead preferred drug and durable medical equipment strategies. Adam is the company's subject matter expert for the billing and coding of medical drugs and related devices and oversees the external relationships with third-party vendors. Adam is currently serving as a key stakeholder in his organization's implementation of the Inflation Reduction Act of 2022 and the CMS 2024 Final Rule change. He is also heavily involved in cross-benefit (medical and pharmacy) strategy and proper benefit adjudication. 

Adam has been an active AMCP member since 2019. He has served on AMCP's Format for Formulary Submissions Committee since early 2022 and is on the Digital Therapeutics subcommittee. He also serves as an AMCP State Advocacy Leader for the state of Massachusetts and has recently been invited to participate in AMCP’s Biologics and Biosimilars Collective Intelligence Consortium.

Ann Johnson

Ann Johnson, PharmD 
President 
Pharmacy Healthcare Solutions, LLC

Ann Johnson, PharmD, is president of Pharmacy Healthcare Solutions, LLC (PHSL) and began working for the company in 2010. PHSL provides business strategy and management consulting services to pharmaceutical manufacturers, DTx companies, managed care organizations, retail pharmacy chains, pharmacy practice management software developers, and law firms. Ann works on a variety of projects, with an emphasis on drug compendia review and product launch support, 340B program assessment and auditing, PBM RFP support, analytics and pricing reimbursement, financial modeling, contract review, operational assessments, and policy and procedure writing and review.  
 
Ann received her Doctor of Pharmacy degree from Duquesne University and graduated with a concentration in pharmacy management. She is an APPE preceptor for the Ohio Northern University Raabe College of Pharmacy and Shenandoah University Bernard J. Dunn School of Pharmacy. Ann previously served as the treasurer and fundraising chair for the Allegheny County Pharmacist Association (ACPA) and is actively involved in the Pennsylvania Pharmacist Association (PPA). She has been a member of AMCP since 2011 and continues to be an active member, currently participating in AMCP’s Digital Therapeutics Advisory Group. She is also an active member of the American Society for Automation in Pharmacy (ASAP), the National Association of Chain Drug Stores (NACDS), and the National Council for Prescription Drug Programs (NCPDP). Ann has authored numerous articles and has been published in several pharmacy journals, including Specialty Pharmacy Times, Inside Patient Care, Computer Talk for the Pharmacist, and MedHealth Outlook.

Theresa Juday

Theresa C. Juday, RPh 
Executive Director, Specialty Product Development 
CVS Health 

As the Executive Director of Specialty Product Development for CVS Health, Ms. Juday leads a team that works to develop innovative payor and plan sponsor strategies focused on managing specialty trend and improving patient outcomes as well as the pharmacy experience for patients, payers and providers. Prior to joining the Innovation Team, she served as a senior clinical professional that supported sales and clinical team members and their plan sponsor clients with specialty pharmacy and trend management solutions.  

Ms. Juday has been with CVS Caremark since 2006. Her previous experience includes developing and implementing payer strategies focused on specialty trends, patient outcomes and adherence programs to improve the specialty pharmacy experience for members, payers and providers. In addition, she has provided continuing education around rare disease in the retail, specialty pharmacy and PBM sectors.  Ms. Juday holds a Bachelor of Science from Butler University’s College of Pharmacy and has been a certified Asthma Educator.

Allyson Mullen

Allyson Mullen, JD 
Director 
Hyman, Phelps & McNamara P.C. 

Allyson Mullen is a director at Hyman, Phelps & McNamara, P.C., a law firm in Washington, D.C. She specializes in providing counsel to medical device and in vitro diagnostic (IVD) manufacturers. Her expertise includes developing regulatory strategy, preparing submissions, drafting policies and procedures, reviewing advertising materials, and addressing enforcement issues. Ms. Mullen is experienced in preparing IDEs, 510(k)s, de novos, and PMAs for premarket activities, as well as handling pre-submissions and breakthrough device designation requests. In the postmarket realm, she advises clients on complaint handling, MDRs, field actions, advertising, promotion, and QSR compliance. Before joining the firm in 2013, she served as in-house counsel at Waters Corporation, an IVD company, where she performed various legal and regulatory functions.

Rob O'Brien

Robert O’Brien, RPh 
Senior Vice President, Specialty Pharmacy 
Real Endpoints

Rob O’Brien, Real Endpoints’ Senior Vice President, has 20+ years of experience in managed care, PBM, and specialty pharmacy. At CVS Health, he held various leadership positions, including directing the Health Plan segment’s clinical team for 8 years and leading a team of specialty clinical experts supporting PBM customers on managing specialty trends and patient care. He also led the sales efforts for medical benefit management solutions and commercialization of the PBM product portfolio. At Real Endpoints, he is developing solutions to maximize appropriate patient access to clinical innovation by collaborating with key stakeholders. Rob attended Albany College of Pharmacy and is a licensed pharmacist in New York. AMCP has enjoyed having Rob as an active member since 2006.

Benjamin Parcher

Benjamin Parcher, PharmD, MS 
Global Market Access Lead, CNS Digital Therapeutics 
Boehringer Ingelheim Pharmaceuticals, Inc. 

Benjamin Parcher, PharmD, MS, is the Global Market Access Lead for Boehringer Ingelheim’s CNS digital therapeutics in schizophrenia. 

He has over 20 years of US and global experience in the health care industry across multiple therapeutic areas. In his current role, he is responsible for driving access strategy in schizophrenia disease through payer-based, collaborative research, and impactful value communications. He has also authored over a dozen studies in the digital space, including key initiatives with the Digital Therapeutic Alliance and the Academy of Managed Care Pharmacy. He holds a Doctor of Pharmacy from the University of California, San Francisco School of Pharmacy, and a Master of Science in Applied Pharmacoeconomics from the University of Florida.

David Putrino

David Putrino, PhD, PT 
Professor 
Icahn School of Medicine at Mount Sinai

David is a physical therapist with a PhD in Neuroscience. He worked as a clinician in Australia, before moving to the United States to study computational neuroscience at Harvard Medical School, MIT, and NYU. He has served as a faculty member at Weill-Cornell Medicine and Burke Medical Research Institute. He is currently the Director of Rehabilitation Innovation for the Mount Sinai Health System, and a Professor of Rehabilitation and Human Performance at the Icahn School of Medicine at Mt Sinai. He works to develop innovative technology solutions for individuals in need of better healthcare accessibility. He works with Red Bull's High Performance Division, the Brooklyn Nets, and the US Olympic team to use evidence-based technologies to improve athletic performance. He is also the “Chief Mad Scientist” of Not Impossible Labs, a group that crowd-sources accessible technological solutions for high-impact humanitarian problems. He is the author of Hacking Health:  How To Make Money and Save Lives in the HealthTech World, which is available from Amazon and Springer-Nature. In 2019, he was named "Global Australian of the Year" for his contributions to health care.

Gail Ryan

Gail Ryan, PharmD 
Director of Pharmaceutical Transformation 
Point32Health

Gail Ryan is the Director of Pharmaceutical Transformation at Point32Health, the parent organization of Harvard Pilgrim Health Care and Tufts Health Plan, two of New England’s most iconic nonprofit health care companies. Point32Health serves over 2 million lives and is an industry leader in innovation and value-based contracting.  As a clinical pharmacist with 20 years of managed care experience, Gail’s practice has spanned the pharmacy benefit, medical drug policy, trend analysis, cost management initiatives, and clinical innovation. In her current role and through partnerships with multi-stakeholders, she is driving equitable access to high-quality, transformative therapies while addressing emerging trends, challenges, and financial risk. Gail holds a Bachelor of Science Degree and a Doctor of Pharmacy, both from the Massachusetts College of Pharmacy and Health Sciences. Gail has also been a valued AMCP member since 2005.

Mahsa Salsabili

Mahsa Salsabili, PharmD, PhD 
Pharmacoeconomics Specialist 
UMass Chan Medical School - ForHealth Consulting

Dr. Salsabili is the Pharmacoeconomics Specialist at ForHealth Consulting within the UMass Chan Medical School. In her current role, she designs analytical approaches and pharmacoeconomic analyses, develops innovative strategies, and performs research to assist clients in pharmaceutical spending and value-based efforts. She is also the primary preceptor of the Applied Pharmacoeconomics/ Pharmacoepidemiology Fellowship program at Clinical Pharmacy Services.  
 
Prior to starting her position at UMass Chan Medical School in 2020, she was a practicing pharmacist in the inpatient setting for 6 years. She has served as clinical pharmacist as well as pharmacy clinical coordinator for several Steward Health Care hospitals, while completing her PhD in Social and Administrative Pharmacy at University of Minnesota with a focus on health policy, Pharmacoeconomics and health informatics. Additionally, she has worked at the PRIME Institute for 4 years conducting pharmaceutical policy and economic analyses. Dr. Salsabili has a bachelor’s in biochemistry from State University of New York Purchase College, Doctor of Pharmacy from University at Buffalo, and has completed a PGY-1 pharmacy residency at Steward Norwood hospital. Mahsa has been a valued AMCP member since 2011.

Scott Whittle

Scott B. Whittle, MD 
Chief Medical Officer 
Meridian Outcomes

Scott Whittle is a leading behavioral health care professional in the Intermountain West, dedicated to advancing health care through whole person care and supporting value-based care. He is passionate about improving the healthcare experience for vulnerable populations, particularly children and adolescents. He started as a medical leader at Primary Children's Medical Center, leading multiple departments and winning awards in medical education. While there, he worked with SelectHealth's CEO to create a behavioral health program, including developing policy and a digital strategy. Currently, he partners with Meridian Outcomes and other organizations to advance legislative and policy work for vulnerable populations, such as creating an Integrated System of Care roadmap for Utah's behavioral health providers. This project includes data sharing and progress metrics, serving as a foundation for value-based contracting expansion.